Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment

Liao, Hsien Tzung; Lin, Yuh Feng; Tsai, Chang Youh; Chou, Chung Tei

doi:10.1016/j.jbspin.2015.03.003

Cited by 27 publications

(26 citation statements)

References 38 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[8][9][10] The Treg/Th17 functional balance is essential for the prevention of autoimmune and inflammatory diseases by preventing deleterious impairment to the host and mounting effective immune responses. 6,12,13 Regulatory T cells, therefore, due to their central role in the self-tolerance and suppression of immune responses can be a contributing factor to the development of AS disease. 6,12,13 Regulatory T cells, therefore, due to their central role in the self-tolerance and suppression of immune responses can be a contributing factor to the development of AS disease.…”

Section: Introductionmentioning

confidence: 99%

The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double‐blind, placebo‐controlled clinical trial

Ahmadi

Hajialilo

Eghbal‐Fard

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Aim Ankylosing spondylitis (AS) is an inflammatory rheumatic disease with increased bone mass in the main sites of inflammation. Regulatory T (Treg) cells have been reported to involve in pathology of AS. This study designed at investigating the effects of nanocurcumin on Treg cell responses in peripheral blood (PB) of AS patients. Methods Test group including 12 AS patients received nanocurcumin daily for 4 months and control group including 12 patients received placebo. The frequency of Treg was measured by flow cytometry. The expression levels of FoxP3 and several associated microRNAs (miRNAs; miR‐27, miR‐17, and miR‐146a) and cytokines including Interleukin‐10 (IL‐10), TGF‐β, and IL‐6 were assessed by real‐time polymerase chain reaction. Furthermore, enzyme‐linked immunosorbent assay was done to determine the secretion levels of cytokines. Results After treatment with nanocurcumin the frequency of Treg cells in AS patients increased significantly. The RT‐PCR data indicated that the expression of miR‐17 and miR‐27 were significantly decreased following nanocurcumin treatment while miR‐146a and FoxP3 were significantly increased. Moreover, nanocurcumin‐treated group had high levels of IL‐10 and TGF‐β and low levels of IL‐6 production than control group. Conclusion The findings suggested that dysregulation of Treg cells in PB influences the AS development and nanocurcumin therapy could regulate the Treg cells, and so could be useful in the treatment of AS and may be other autoimmune diseases. This study is registered with IRCT.ir, number IRCT2017052927520N7.

show abstract

Section: Introductionmentioning

confidence: 99%

The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double‐blind, placebo‐controlled clinical trial

Ahmadi

Hajialilo

Eghbal‐Fard

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…There are only few studies addressing the question of how TNF inhibitors influence the T-cell repertoire in AS [10-14]. Most of the existing examinations, however, have operated with only few T-cell subsets [10], and some of them examined only the role of T reg and/or Th17 cells [11, 12, 15]. The available articles do not make a distinction between peripheral and/or axial AS, and they use non-radiographic spondyloarthritis as an early stage of AS [10, 13] rather than as an individually existing entity.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Anti-TNF Therapy on CD4+ and CD8+ Cell Subsets in Ankylosing Spondylitis

et al. 2017

View full text Add to dashboard Cite

Objectives: Ankylosing spondylitis (AS) is a chronic, progressive immune-mediated inflammatory disease, driven primarily by Th1 and Th17 cells. Anti-TNF therapies are successfully used in AS to achieve and maintain remission. However, their influence on the composition of T-cell subsets is not clear. We aimed to characterize the changes in the T-cell repertoire after a long-term anti-TNF treatment in AS patients. Methods: Twenty-two AS patients under long-term anti-TNF therapy were evaluated (15 anti-TNF responders and 7 nonresponders). A wide range of cell subtypes was analyzed with flow cytometry and compared with therapy-naïve and short-term data too. Results: Key findings include decreased proportions of naïve CD4 and CD8 cells, increased frequencies of Th1 and Th17 cells and higher Th1/Th2 ratios in the long-term anti-TNF-treated patients (responders, nonresponders and total), which was found to be significant not only when compared with healthy controls, but also with therapy-naïve and short-term anti-TNF-treated AS patients. We noted several alterations within the various activated T-cell subsets – increase in CD4HLADR cells in responders, in CD8HLADR cells in the whole AS group and in responders, and in CD4CD25 cells in responders, and decrease in CD4CD69 cell percentages in long-term treated patients – becoming evident only after long-term anti-TNF therapy. Conclusions: This study provides a comprehensive assessment of the impact of anti-TNF therapy on the T-cell repertoire in AS. Changes in T-cell phenotype seem to develop progressively during therapy, even in inactive disease, and reflect an ongoing effector T-cell differentiation and activation, along with the parallel compensatory increase in regulatory T cells.

show abstract

“…In contradiction to the previous investigations, Liao et al have detected increased Treg frequencies in 15 AS patients, moreover adalimumab therapy has reduced the Treg prevalence (55). Important limitations are, however, that most of the existing examinations have examined only the role of Tregs and/orTh17 cells (52,53,55), and many of the available articles did not make a distinction between peripheral and/or axial AS, and they use non-radiographic spondyloarthritis as an early stage of AS (49,56) rather than as an individually existing entity. Importantly, only one study analyzed patients with relatively long-standing anti-TNF treatment (6 months) (52), whereas two further investigations, including our previous work, followed the T cell repertoire only for short-term (6 weeks) (53,54), although we have already demonstrated in our preceding study of RA patients that there are profound differences in the T cell subset distribution as measured after short-term or long-term follow-up (57).…”

Section: Ankylosing Spondylitismentioning

confidence: 61%

“…In contrast, another study on 15 AS patients has reported on an increase in Th17 cell prevalence in anti-TNF-treated patients (53). In contradiction to the previous investigations, Liao et al have detected increased Treg frequencies in 15 AS patients, moreover adalimumab therapy has reduced the Treg prevalence (55). Important limitations are, however, that most of the existing examinations have examined only the role of Tregs and/orTh17 cells (52,53,55), and many of the available articles did not make a distinction between peripheral and/or axial AS, and they use non-radiographic spondyloarthritis as an early stage of AS (49,56) rather than as an individually existing entity.…”

Section: Ankylosing Spondylitismentioning

confidence: 84%

See 1 more Smart Citation

Investigation of the adaptive immune response in immune-mediated diseases

Dulic¹

View full text Add to dashboard Cite

show abstract

Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment

Cited by 27 publications

References 38 publications

The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double‐blind, placebo‐controlled clinical trial

The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double‐blind, placebo‐controlled clinical trial

The Impact of Anti-TNF Therapy on CD4+ and CD8+ Cell Subsets in Ankylosing Spondylitis

Investigation of the adaptive immune response in immune-mediated diseases

Contact Info

Product

Resources

About